End-of-day quote
Korea S.E.
06:00:00 2024-05-21 pm EDT
|
5-day change
|
1st Jan Change
|
21,950
KRW
|
+0.23%
|
|
0.00%
|
-7.19%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
479,396
|
400,643
|
348,913
|
477,988
|
229,651
|
289,667
|
Enterprise Value (EV)
1 |
458,178
|
386,210
|
315,789
|
350,575
|
144,102
|
223,976
|
P/E ratio
|
15.8
x
|
14.3
x
|
7.8
x
|
120
x
|
-3.82
x
|
7.55
x
|
Yield
|
1.13%
|
1.14%
|
1.3%
|
1.24%
|
2.67%
|
2.22%
|
Capitalization / Revenue
|
1.27
x
|
0.89
x
|
0.67
x
|
0.82
x
|
0.35
x
|
0.38
x
|
EV / Revenue
|
1.21
x
|
0.86
x
|
0.6
x
|
0.6
x
|
0.22
x
|
0.3
x
|
EV / EBITDA
|
5.46
x
|
4.13
x
|
2.75
x
|
3.36
x
|
1.2
x
|
1.47
x
|
EV / FCF
|
-41.8
x
|
25.5
x
|
29.5
x
|
-9.06
x
|
-25.9
x
|
-4.45
x
|
FCF Yield
|
-2.39%
|
3.92%
|
3.39%
|
-11%
|
-3.87%
|
-22.5%
|
Price to Book
|
1.26
x
|
1.06
x
|
0.84
x
|
0.89
x
|
0.49
x
|
0.58
x
|
Nbr of stocks (in thousands)
|
12,570
|
12,566
|
12,525
|
12,415
|
12,248
|
12,248
|
Reference price
2 |
38,138
|
31,882
|
27,857
|
38,500
|
18,750
|
23,650
|
Announcement Date
|
3/7/19
|
3/11/20
|
3/11/21
|
3/23/22
|
3/23/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
378,687
|
449,423
|
523,048
|
579,937
|
664,365
|
758,380
|
EBITDA
1 |
83,843
|
93,566
|
114,835
|
104,491
|
120,376
|
151,929
|
EBIT
1 |
67,996
|
72,905
|
89,249
|
75,170
|
86,735
|
115,949
|
Operating Margin
|
17.96%
|
16.22%
|
17.06%
|
12.96%
|
13.06%
|
15.29%
|
Earnings before Tax (EBT)
1 |
77,297
|
71,150
|
111,793
|
62,502
|
655.3
|
119,633
|
Net income
1 |
28,906
|
26,657
|
42,696
|
3,995
|
-60,254
|
38,384
|
Net margin
|
7.63%
|
5.93%
|
8.16%
|
0.69%
|
-9.07%
|
5.06%
|
EPS
2 |
2,415
|
2,227
|
3,573
|
321.7
|
-4,903
|
3,134
|
Free Cash Flow
1 |
-10,971
|
15,128
|
10,714
|
-38,714
|
-5,572
|
-50,300
|
FCF margin
|
-2.9%
|
3.37%
|
2.05%
|
-6.68%
|
-0.84%
|
-6.63%
|
FCF Conversion (EBITDA)
|
-
|
16.17%
|
9.33%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
56.75%
|
25.09%
|
-
|
-
|
-
|
Dividend per Share
2 |
431.9
|
362.8
|
362.8
|
476.2
|
500.0
|
525.0
|
Announcement Date
|
3/7/19
|
3/11/20
|
3/11/21
|
3/23/22
|
3/23/23
|
3/20/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
21,217
|
14,433
|
33,124
|
127,413
|
85,549
|
65,691
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-10,971
|
15,128
|
10,714
|
-38,714
|
-5,572
|
-50,300
|
ROE (net income / shareholders' equity)
|
11.9%
|
10.2%
|
14.7%
|
4.24%
|
-4.01%
|
10.8%
|
ROA (Net income/ Total Assets)
|
6.62%
|
6.44%
|
6.6%
|
4.21%
|
4.29%
|
5.66%
|
Assets
1 |
436,344
|
413,920
|
647,242
|
94,921
|
-1,404,329
|
678,264
|
Book Value Per Share
2 |
30,257
|
30,122
|
33,069
|
43,321
|
37,909
|
40,972
|
Cash Flow per Share
2 |
5,799
|
5,836
|
8,752
|
17,591
|
23,077
|
19,731
|
Capex
1 |
52,638
|
35,330
|
64,126
|
144,448
|
75,924
|
79,774
|
Capex / Sales
|
13.9%
|
7.86%
|
12.26%
|
24.91%
|
11.43%
|
10.52%
|
Announcement Date
|
3/7/19
|
3/11/20
|
3/11/21
|
3/23/22
|
3/23/23
|
3/20/24
|
|
1st Jan change
|
Capi.
|
---|
| -7.19% | 197M | | +16.90% | 79.38B | | +9.28% | 8.74B | | -14.24% | 4.94B | | +49.95% | 4.7B | | +5.96% | 3.98B | | +12.74% | 2.28B | | -23.57% | 2.28B | | +17.77% | 2.14B | | -32.28% | 2.12B |
Specialty & Advanced Pharmaceuticals
|